TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis

Adam P. Gregory, Calliope A. Dendrou, Kathrine E. Attfield, Aiden Haghikia, Dionysia K. Xifara, Falk Butter, Gereon Poschmann, Gurman Kaur, Lydia Lambert, Oliver A. Leach, Simone Prömel, Divya Punwani, James H. Felce, Simon J. Davis, Ralf Gold, Finn C. Nielsen, Richard M. Siegel, Matthias Mann, John I. Bell, Gil McVean and Lars Fugger ()
Additional contact information
Adam P. Gregory: MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
Calliope A. Dendrou: John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
Kathrine E. Attfield: John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
Aiden Haghikia: John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
Dionysia K. Xifara: Wellcome Trust Centre for Human Genetics, Roosevelt Drive, University of Oxford, Oxford OX3 7BN, UK
Falk Butter: Max-Planck-Institute of Biochemistry, D-82152 Martinsried, Germany
Gereon Poschmann: Molecular Proteomics Laboratory, Biologisch-Medizinisches Forschungszentrum, Heinrich-Heine Universität Düsseldorf, D-40225 Düsseldorf, Germany
Gurman Kaur: MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
Lydia Lambert: John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
Oliver A. Leach: John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
Simone Prömel: John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
Divya Punwani: MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
James H. Felce: MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
Simon J. Davis: MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
Ralf Gold: St. Josef-Hospital Bochum, Ruhr-University Bochum, 44791 Bochum, Germany
Finn C. Nielsen: Center for Genomic Medicine, Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen Ø, Denmark
Richard M. Siegel: Immunoregulation Section, Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH, 10 Center Drive
Matthias Mann: Max-Planck-Institute of Biochemistry, D-82152 Martinsried, Germany
John I. Bell: Richard Doll Building, Roosevelt Drive, University of Oxford, Oxford OX3 7DG, UK
Gil McVean: Wellcome Trust Centre for Human Genetics, Roosevelt Drive, University of Oxford, Oxford OX3 7BN, UK
Lars Fugger: MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK

Nature, 2012, vol. 488, issue 7412, 508-511

Abstract: Genome-wide association studies in combination with functional analyses identify a genetic variant that explains why anti-tumour necrosis factor therapy, used in several autoimmune diseases, exacerbates multiple sclerosis.

Date: 2012
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/nature11307 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:488:y:2012:i:7412:d:10.1038_nature11307

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature11307

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().